Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of sotatercept added to background therapy for pulmonary arterial hypertension
MOH_2021-02-01_009641Phase 3Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Standard PAH therapy + placebo with Standard PAH therapy + sotatercept (2 arms). Primary endpoint: Primary endpoint not reported. Started Jan 2021; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2021-02-01_009641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-01_009641.